

June 28, 2019

**Pharmacy Announcement** 

## Pharmacy and Therapeutics (P&T) Committee Makes Changes to Preferred Drug List (PDL) Effective July 1, 2019

On March 28, 2019, the Pharmacy and Therapeutics (P&T) Committee of the Nevada Department of Health and Human Services' Division of Health Care Financing and Policy met to review new and existing therapeutic drug classes on the Nevada Medicaid Preferred Drug List (PDL).

The actions taken by the committee are indicated below. All changes are effective July 1, 2019. The complete PDL is posted on the "Preferred Drug List" webpage.

Drug Class	Drugs Added As Preferred	Drugs Added As Non-Preferred
Analgesics: Analgesic/Miscellaneous: Neuropathic Pain/Fibromyalgia Agents		Lyrica® CR Qutenza®
Anti-infective Agents: Antivirals: Anti- hepatitis Agents	Ledipasvir/Sofosbuvir Sofosbuvir/Velpatasvir	
Anti-infective Agents: Antivirals: Influenza Agents	Xofluza®	
Autonomic Agents: Sympathomimetics: Self-Injectable Epinephrine		Symjepi <sup>®</sup>
Dermatological Agents: Topical Anti- infectives: Topical Antifungals: Onychomycosis Agents	Removal of Topical Antifungals from the PDL	
Hormones and Hormone Modifiers: Androgens		Androgel® Testosterone Solution
Neurological Agents: Anti-Migraine Agents: Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists (NEW)	Aimovig® Ajovy®	Emgality®
Ophthalmic Agents: Antiglaucoma Agents		Dorzolamide HCI/Timolol maleate Xelpros®
Ophthalmic Agents: Ophthalmics for Dry Eye Disease		Cequa®
Toxicology Agents: Substance Abuse Agents*	Sublocade® Vivitrol®	Buprenorphine/Naloxone Film and Tabs

<sup>\*</sup>No longer indicated on PDL as Mixed Opiate Agonists/Antagonists.